6. Women with high breast density
In the context of an organised population-based screening programme, for asymptomatic women with high mammographic breast density, the ECIBC's Guidelines Development Group (GDG) suggests:
- not implementing tailored screening with automated breast ultrasound system (ABUS) (conditional recommendation, very low certainty of the evidence)
- not implementing tailored screening with hand-held ultrasound (HHUS) (conditional recommendation, low certainty of the evidence)
Tailored screening with HHUS
Issued on: February 2017
Healthcare question
Should tailored screening with hand-held ultrasound based on high mammographic breast density, in addition to mammography, vs. mammography alone be used for early detection of breast cancer in asymptomatic women?
Recommendation
For asymptomatic women, with high mammographic breast density and a negative mammography, in the context of an organised population-based screening programme, the ECIBC's Guidelines Development Group (GDG) suggests not implementing tailored screening with hand-held ultrasound (HHUS), where such is not already the practice.
Recommendation strength
| Conditional recommendation |
| Low certainty of the evidence |
Justification
The conditional recommendation (rather than strong) against tailored screening with hand-held ultrasound (HHUS) in addition to mammography screening over mammography screening alone in women with high mammographic breast density, in the context of an organised screening programme, is the result of a balance of the health effects that does not favour either the intervention nor the comparison, in the context of low certainty in the evidence about these effects, and the large resource (cost) associated with HHUS. There is an improved detection rate of HHUS plus mammography over mammography alone, however, this improvement is smaller as compared to alternative imaging modalities such as DBT (see recommendation for this intervention) although no direct comparison of HHUS and DBT was made.
In settings that are not already using HHUS in tailored screening, it is likely not useful to implement this for screening programmes
Considerations for implementation and policy making
- If resources and implementation are not a concern, or where HHUS has already been implemented, countries may decide to keep HHUS-based screening programmes.
- The GDG members felt that information and education for women about mammographic breast density is critical. The opinion of women regarding HHUS depends on the quality of the information provided to them with regards to the evidence behind this modality for tailored screening, including the information concerning the limitations or uncertainty about the effects of HHUS and inter-operator variability.
- The GDG expressed concern about the quality assurance for HHUS in contexts where training is variable and screening is opportunistic and not organised.
- No new technology would likely be necessary in most settings, although some institutions may not have the ultrasound equipment which fulfils the requirements for performing breast ultrasound.
- There are additional training requirements for radiologists performing HHUS.
- Pressure to implement HHUS exists, which may have to be considered with regards to the conditional recommendation against based on the evidence reviewed by the GDG.
Monitoring and evaluation
Quality assurance of HHUS appears challenging to conduct or implement. In settings where they decide to implement HHUS, the GDG recommends consideration be given to quality assurance of HHUS.
Supporting material
- Organised vs. non-organised screening
- Double vs. single reading in mammograpy screening
- Communication skills training
- Communication with care providers
- Optimal number of mammography readings
- Specialised training
- Risk stratification
- Women aged 40-44: screening vs. no screening
- Women aged 45-49: screening vs. no screening
- Women aged 45-49: annual vs. biennial screening
- Women aged 45-49: annual vs. triennial screening
- Women aged 45-49: triennial vs. biennial screening
- Women aged 50-69: screening vs. no screening
- Women aged 50-69: annual vs. biennial screening
- Women aged 50-69: annual vs. triennial screening
- Women aged 50-69: triennial vs. biennial screening
- Women aged 70-74: screening vs. no screening
- Women aged 70-74: annual vs. biennial screening
- Women aged 70-74: annual vs. triennial screening
- Women aged 70-74: triennial vs. biennial screening
- Single reading with AI support
- Double reading with AI support
- Screening with tomosynthesis vs. mammography
- Screening with tomosynthesis plus mammography vs. mammography alone
- Tailored screening with tomosynthesis
- Screening with tomosynthesis vs. mammography
- Tailored screening with MRI
- Tailored screening with ABUS
- Tailored screening with HHUS
- Informing about benefits and harms: use of decision aids
- Informing about benefits and harms: Numbers in addition to plain language
- Informing about benefits and harms: Infographics in addition to plain language
- Informing about benefits and harms: Story telling in addition to plain language
- Inviting women to screening: letter vs. no invitation
- Inviting socially disadvantaged women to screening: Targeted vs. general communication strategy
- Inviting women with an intellectual disability to screening
- Inviting non-native speakers to screening
- Inviting socially disadvantaged women to screening: Tailored vs. targeted communication strategy
- Inviting socially disadvantaged women to screening: Tailored vs. general communication strategy
- Inviting women to subsequent screening rounds: letter vs. no invitation
- Inviting women to screening: letter with fixed appointment vs. letter
- Inviting women to subsequent screening rounds: letter with fixed appointment vs. lett
- Inviting women to screening: letter with GP signature vs. letter
- Inviting women to subsequent screening rounds: letter with GP signature vs. letter
- Inviting women to screening: letter followed by phone call vs. letter
- Inviting women to subsequent screening rounds: letter followed by phone call vs. letter
- Inviting women to screening: letter followed by phone call vs. no invitation
- Inviting women to screening: letter followed by written reminder vs. letter
- Inviting women to subsequent screening rounds: letter followed by written reminder vs. letter
- Inviting women to screening: letter followed by face to face intervention vs. letter
- Inviting women to subsequent screening rounds: letter followed by face to face intervention vs. letter
- Inviting women to screening: e-mail vs. letter
- Inviting women to screening: automated telephone call vs. letter
- Inviting women to screening: letter followed by automated telephone call vs. letter
- Inviting women to screening: letter followed by SMS notification vs. letter
- Inviting women to screening: letter followed by personalised phone call vs. automated phone call
- Negative result: letter vs. nothing
- Further assessment: letter followed by a phone call
- Further assessment: timing of results
- Negative result: phone call vs. letter
- Negative result: face to face interview vs. letter
- Negative result: timing of results
- Tomosynthesis vs. assessment mammography
- Obtaining a sample from a suspicious breast lesion
- Type of guidance for needle core biopsy
- Stage 1: conventional exams
- Stage 1: PET-CT exams
- Stage 2: conventional exams
- Stage 2: PET-CT exams
- Stage 3: conventional exams
- Stage 3: PET-CT exams
- Stage 3: conventional exams plus PET-CT
- Use of clip-marking
- Additional magnetic resonance imaging
- Contrast-enhanced mammography
- Threshold of oestrogen for endocrine therapy
- Threshold of progesterone for endocrine therapy
- Multigene testing: 70 gene signature at low clinical risk
- Multigene testing: 70 gene signature at high clinical risk
- Multigene testing: 21 gene recurrence score
- Organising screening programmes
- Risk stratification
- Women 40-44
- Women 45-49
- Women 50-69
- Women 70-74
- Women with high breast density
- General Population
- Vulnerable Population
- Informing women about their results
- Women recalled due to suspicious lesions
- Obtaining a sample from a suspicious lesion
- Type of guidance for needle core biopsy
- Stage 1
- Stage 2
- Stage 3
- Planning surgical treatment
- Hormone receptor to guide use of endocrine therapy
- Multigene testing to guide use of chemotherapy